Brain NAD in Alzheimer's Disease
ConditionAlzheimer Disease (AD)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age65-80
SponsorFlorida Atlantic University
About this trial
The goal of this observational study is to learn about the levels of nicotinamide adenine dinucleotide (NAD) in the brains of people with Alzheimer's disease. The study aims to determine if brain NAD levels are lower in people with Alzheimer's disease compared with people of the same age group who do not have Alzheimer's disease.
Participants with or without Alzheimer's disease will have a brain imaging session where NAD will be measured using magnetic resonance spectroscopy (MRS). Eight months later, they will have a second, similar, brain imaging session.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Participants are able to come to the Florida Atlantic University Clinical Research Unit, are verbal and ambulatory.
Age 65 to 80 included.
People with Alzheimer's disease (AD): AD diagnosis established by the person's physician according to the following criteria: clinical diagnosis AND either positive amyloid PET-scan or FDA-approved positive CSF or blood test.
Disqualifiers
Under the age of 65 or over the age of 80.
Advanced dementia such that the person would require sedation for undergoing an MRI scan.
Receiving anti-amyloid intravenous treatments Leqembi or Kinsula.
Having an MRI-incompatible pacemaker or other MRI-incompatible hardware (e.g. comprising a metallic part).
Trial population
Primary care clinic, community.
Trial design
Design model
Case-control
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
20 Participants
are grouped into 2 trial groupsGroup A: Alzheimer's disease group
Group B: Control group
Trial outcomes
Primary outcomes
1
Brain NAD
NAD levels measured by 1H-MRS
Time frame
At enrollment and 8 months after enrollmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov